


REGISTERED NUMBER: 01506034 (England and Wales)

FORUM BIOSCIENCE HOLDINGS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2017

SATURDAY



A76R8L60

A16

26/05/2018

#169

COMPANIES HOUSE

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

	Page
Company Information	1
Balance Sheet and Income Statement	2
Notes to the Financial Statements	3

FORUM BIOSCIENCE HOLDINGS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2017

DIRECTOR: H Van Der Wal

SECRETARY: N Copp

REGISTERED OFFICE: Crown House
2-8 Gloucester Road
Redhill
Surrey
RH1 1FH

REGISTERED NUMBER: 01506034

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

BALANCE SHEET
31 DECEMBER 2017

	Notes	2017 £	2016 £
FIXED ASSETS			
Investments	2	4	4
CREDITORS			
Amounts falling due within one year	3	<u>2</u>	<u>2</u>
NET CURRENT LIABILITIES		<u>(2)</u>	<u>(2)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>2</u>	<u>2</u>
CAPITAL AND RESERVES			
Called up share capital		<u>2</u>	<u>2</u>
SHAREHOLDERS' FUNDS		<u>2</u>	<u>2</u>

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the year ended 31 December 2017.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2017 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved and authorised for issue by the director on 30th April 2018 and were signed by:



H. Van Der Wal - Director

INCOME STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017

During the financial year and the preceding financial year the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

The notes form part of these financial statements

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on the going concern basis.

Preparation of consolidated financial statements

The financial statements contain information about Forum Bioscience Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its parent, Forum Products Holdings Limited, .

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

2. FIXED ASSET INVESTMENTS

	Shares in group undertakings £
COST	
At 1 January 2017	
and 31 December 2017	<u>4</u>
NET BOOK VALUE	
At 31 December 2017	<u>4</u>
At 31 December 2016	<u>4</u>

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Forum Products (Ireland) Limited

Registered office:

Nature of business: Dormant

	% holding	2017 £	2016 £
Class of shares:	100.00		
Ordinary			
Aggregate capital and reserves		<u>2</u>	<u>2</u>

Quantum Generics Limited

Registered office:

Nature of business: Dormant

	% holding	2017 £	2016 £
Class of shares:	100.00		
Ordinary			
Aggregate capital and reserves		<u>2</u>	<u>2</u>

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2017

3. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2017	2016
	£	£
Amounts owed to group undertakings	<u>2</u>	<u>2</u>

4. **RELATED PARTY DISCLOSURES**

Section 33 of FRS 102 "Related Party Disclosures" requires disclosure of the details of material transactions between the reporting entity and related parties. The company is exempt under the terms of Section 33 of FRS 102 from disclosing related party transactions with entities that are part of the Forum Products Holdings Limited group.

5. **ULTIMATE CONTROLLING PARTY**

The company's ultimate controlling party is Stichting Barentz Beheer (a Trust)